WGS
GeneDx Holdings Corp.Healthcare · $2.6B market cap
Verdict
We can't put a fair value on WGS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow WGS
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds WGS right now. In Q2 2026, 1 sold out. Who we track
Moves in Q2 2026
Sold out: Polen Capital Management
Insider activity
Since Sep 1, 2026: no open-market purchases, 3 sales worth $450K and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-09
Sold
$108K
Stueland Katherine
CHIEF EXECUTIVE OFFICER · 2026-09-09
Sold
$311K
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-01
Sold
$31K
Other filings
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx…
Medical - Diagnostics & Research
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works